Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
Kristen L NowakFederica MorettiNicole BussolaCortney N SteeleAdriana V GregoryTimothy L KlineSumana RamanathanGiovanni TraplettiCesare FurlanelloLinda McCormickMichel ChoncholPublished in: American journal of kidney diseases : the official journal of the National Kidney Foundation (2024)
We analyzed images from a previous study with the drug tolvaptan conducted in patients with autosomal dominant polycystic kidney disease (ADPKD) to measure the amount of fat tissue surrounding the kidneys (visceral fat). We had previously shown body mass index can predict kidney growth in this population; now we determined whether visceral fat was an important factor associated with kidney growth. Using a machine learning tool to automate measurement of fat in images, we observed that visceral fat was independently associated with kidney growth, that it was a better predictor of faster kidney growth in lean patients than body mass index, and that having more visceral fat made treatment of ADPKD with tolvaptan less effective.
Keyphrases
- polycystic kidney disease
- adipose tissue
- insulin resistance
- machine learning
- body mass index
- fatty acid
- deep learning
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- optical coherence tomography
- ejection fraction
- type diabetes
- randomized controlled trial
- emergency department
- metabolic syndrome
- atrial fibrillation
- weight gain
- study protocol
- patient reported outcomes
- big data
- phase ii
- open label
- acute heart failure